Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Waystar Holding Corp.WAY · Entity 1420 | Director | June 03, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Waystar Holding Corp.
Report date June 03, 2026 · Filed September 25, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,275 |
Reported balance
After 2026-06-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 10,446 · Balance 24,275 F1: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. This amended Form 4 is being filed solely to correct the number of RSUs granted from 9,303 to 10,446. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. This amended Form 4 is being filed solely to correct the number of RSUs granted from 9,303 to 10,446.
F2: Includes unvested RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Signify Health, Inc.
Report date March 29, 2023 · Filed March 29, 2023
Section 16 reporting ended · disclosed 2023-03-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-29 transaction · row 4
3 source rows · reconciled sequenceRow 1 · 2023-03-29 · Conversion · Acquired 24,173 · Balance 60,661 F1: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. Row 2 · 2023-03-29 · Disposition to issuer · Disposed 14,672 · Balance 45,989 F2: Pursuant to the Merger Agreement, each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU"), that was (i) outstanding immediately prior to the effective time of the merger (the "Effective Time") to the extent vested and unsettled and (ii) any Issuer RSU that was outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer (each, a "Cash-Out RSU"), was cancelled and converted into the right to receive an amount in cash equal to (1) to $30.50 (the "Per Share Consideration") multiplied by (2) the number of shares of the Issuer's Class A Common Stock subject to such Cash-Out RSU. Row 4 · 2023-03-29 · Disposition to issuer · Disposed 45,989 · Balance 0 F4: Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration. |
| Class B Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-29 transaction · row 3
1 source rowRow 3 · 2023-03-29 · Disposition to issuer · Disposed 24,173 · Balance 0 F3: Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled. |
| LLC Units in Cure Aggregator, LLCSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-29 · Conversion · Disposed 24,173 · Balance 0 F1: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock.
F2: Pursuant to the Merger Agreement, each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU"), that was (i) outstanding immediately prior to the effective time of the merger (the "Effective Time") to the extent vested and unsettled and (ii) any Issuer RSU that was outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer (each, a "Cash-Out RSU"), was cancelled and converted into the right to receive an amount in cash equal to (1) to $30.50 (the "Per Share Consideration") multiplied by (2) the number of shares of the Issuer's Class A Common Stock subject to such Cash-Out RSU.
F3: Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled.
F4: Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Sep 25, 2026 16:37 UTC Amendment | Waystar Holding Corp. WAY · Entity 1420 | GrantCommon Stock | 10,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001843139-26-000005 · wk-form4a_1790354262.xml · nonDerivative · entry 1 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,275 F1 · shares: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. This amended Form 4 is being filed solely to correct the number of RSUs granted from 9,303 to 10,446. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 03, 2026 Filed Jun 3, 2026 22:24 UTC | Waystar Holding Corp. WAY · Entity 1420 | GrantCommon Stock | 9,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001843139-26-000003 · wk-form4_1780525443.xml · nonDerivative · entry 1 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,132 F1 · shares: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 16, 2025 Filed Jun 16, 2025 20:04 UTC | Waystar Holding Corp. WAY · Entity 1420 | GrantCommon Stock | 5,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-059852 · tm2518062-5_4seq1.xml · nonDerivative · entry 1 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,829 F1 · shares: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 4, 2026 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:34 UTC | Waystar Holding Corp. WAY · Entity 1420 | GrantCommon Stock | 8,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-070878 · tm2416795-13_4seq1.xml · nonDerivative · entry 1 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,695 F1 · kind: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 6, 2025 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of common stock, $0.01 par value per share upon settlement. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:54 UTC | Signify Health, Inc. SGFY · Entity 114996 | ConversionLLC Units in Cure Aggregator, LLC · Derivative | 24,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009934 · doc4.xml · derivative · entry 5 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 24,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. F1 · price: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. F1 · derivative.exercise_date: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. F1 · derivative.expiration_date: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:54 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerClass A Common Stock | 45,989 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009934 · doc4.xml · nonDerivative · entry 4 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · kind: Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration. F4 · price: Pursuant to the Merger Agreement, each share of Class A Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled and converted into the right to receive the Per Share Consideration. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:54 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerClass B Common Stock | 24,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009934 · doc4.xml · nonDerivative · entry 3 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled. F3 · price: Pursuant to the Merger Agreement, each share of Class B Common Stock outstanding and held by the Reporting Person immediately prior to the Effective Time, was cancelled. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:54 UTC | Signify Health, Inc. SGFY · Entity 114996 | Disposition to issuerClass A Common Stock | 14,672 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009934 · doc4.xml · nonDerivative · entry 2 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,989 F2 · kind: Pursuant to the Merger Agreement, each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU"), that was (i) outstanding immediately prior to the effective time of the merger (the "Effective Time") to the extent vested and unsettled and (ii) any Issuer RSU that was outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer (each, a "Cash-Out RSU"), was cancelled and converted into the right to receive an amount in cash equal to (1) to $30.50 (the "Per Share Consideration") multiplied by (2) the number of shares of the Issuer's Class A Common Stock subject to such Cash-Out RSU. F2 · price: Pursuant to the Merger Agreement, each restricted stock unit with respect to shares of the Issuer's Class A Common Stock (each, an "Issuer RSU"), that was (i) outstanding immediately prior to the effective time of the merger (the "Effective Time") to the extent vested and unsettled and (ii) any Issuer RSU that was outstanding immediately prior to the Effective Time and was held by any person who is a non-employee director, consultant or independent contractor engaged by the Issuer (each, a "Cash-Out RSU"), was cancelled and converted into the right to receive an amount in cash equal to (1) to $30.50 (the "Per Share Consideration") multiplied by (2) the number of shares of the Issuer's Class A Common Stock subject to such Cash-Out RSU. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 08:54 UTC | Signify Health, Inc. SGFY · Entity 114996 | ConversionClass A Common Stock | 24,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-009934 · doc4.xml · nonDerivative · entry 1 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. F1 · price: On March 29, 2023, pursuant to that certain Agreement and Plan of Merger, dated September 2, 2022, between the Issuer, CVS Pharmacy, Inc. ("Parent") and Noah Merger Sub, Inc. (the "Merger Agreement"), the Reporting Person received 24,173 shares of the Issuer's Class A Common Stock ("Class A Common Stock") pursuant to the exchange by Cure Aggregator, LLC of LLC Units of Cure TopCo, LLC ("LLC Units") for the Issuer's Class A Common Stock on a one-for one basis (and the corresponding cancellation of an equal number of shares of the Issuer's Class B Common Stock ("Class B Common Stock")), and the subsequent distribution by Cure Aggregator, LLC to the Reporting Person of such shares of Class A Common Stock. Read SEC document |
| May 19, 2022 Filed May 23, 2022 19:22 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantClass A Common Stock | 14,672 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-009029 · dp173662_4-riefberg.xml · nonDerivative · entry 1 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,488 F1 · shares: Represents a grant of restricted stock units on May 19, 2022 that will vest on the first anniversary of the grant date. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 20:12 UTC | Signify Health, Inc. SGFY · Entity 114996 | PurchaseClass A Common Stock | 13,900 | $24.00 | $333,600.00 |
DisclosureSEC source: 0000950103-21-002455 · dp146254_4-riefberg.xml · nonDerivative · entry 3 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,816 F3 · shares: These securities were purchased through the Issuer's directed share program in connection with its initial public offering. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 20:12 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantClass A Common Stock | 7,916 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-002455 · dp146254_4-riefberg.xml · nonDerivative · entry 2 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,916 F2 · shares: Represents a grant of restricted stock units on February 16, 2021 that will vest on the first anniversary of the grant date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 20:12 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantLLC Units in Cure Aggregator, LLC · Derivative | 24,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-002455 · dp146254_4-riefberg.xml · derivative · entry 4 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,173 Underlying: Class A Common Stock · 24,173 shares Expires not disclosed F4 · derivative.exercise_price: The LLC Units service-vest 25% on each of the first four anniversaries of November 27, 2019 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified cash-on-cash return thresholds. Upon vesting, each LLC Unit may be converted by the holder into an LLC Unit of Cure TopCo, LLC, which may thereafter be redeemed for, together with the cancellation of a share of Class B common stock, one share of Class A common stock or a cash payment equal to the volume weighted average market price of one share of Class A common stock for each LLC Unit redeemed. The LLC Units do not expire. F1 · shares: These securities were acquired through the conversion prior to the completion of the Issuer's initial public offering of historical interests held by the reporting person in Cure Aggregator, LLC. F4 · derivative.exercise_date: The LLC Units service-vest 25% on each of the first four anniversaries of November 27, 2019 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified cash-on-cash return thresholds. Upon vesting, each LLC Unit may be converted by the holder into an LLC Unit of Cure TopCo, LLC, which may thereafter be redeemed for, together with the cancellation of a share of Class B common stock, one share of Class A common stock or a cash payment equal to the volume weighted average market price of one share of Class A common stock for each LLC Unit redeemed. The LLC Units do not expire. F4 · derivative.expiration_date: The LLC Units service-vest 25% on each of the first four anniversaries of November 27, 2019 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified cash-on-cash return thresholds. Upon vesting, each LLC Unit may be converted by the holder into an LLC Unit of Cure TopCo, LLC, which may thereafter be redeemed for, together with the cancellation of a share of Class B common stock, one share of Class A common stock or a cash payment equal to the volume weighted average market price of one share of Class A common stock for each LLC Unit redeemed. The LLC Units do not expire. F4 · derivative.underlying: The LLC Units service-vest 25% on each of the first four anniversaries of November 27, 2019 and performance-vest based on the achievement by New Mountain Capital, LLC and its affiliates of specified cash-on-cash return thresholds. Upon vesting, each LLC Unit may be converted by the holder into an LLC Unit of Cure TopCo, LLC, which may thereafter be redeemed for, together with the cancellation of a share of Class B common stock, one share of Class A common stock or a cash payment equal to the volume weighted average market price of one share of Class A common stock for each LLC Unit redeemed. The LLC Units do not expire. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 20:12 UTC | Signify Health, Inc. SGFY · Entity 114996 | GrantClass B Common Stock | 24,173 | $0.01 | $241.73 |
DisclosureSEC source: 0000950103-21-002455 · dp146254_4-riefberg.xml · nonDerivative · entry 1 Riefberg Vivian E. · CIK 0001843139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,173 F1 · shares: These securities were acquired through the conversion prior to the completion of the Issuer's initial public offering of historical interests held by the reporting person in Cure Aggregator, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.